Trial Profile
A Phase II Study of Treatment of Brain Metastases From Non-Small Cell Lung Cancer With Concurrent Whole Brain Radiation Therapy and Pemetrexed.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 Jun 2017
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary)
- Indications Cancer metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 22 Jun 2017 Status changed from completed to discontinued due to slow accrual.
- 28 Feb 2012 Actual patient number is 10 according to ClinicalTrials.gov.
- 16 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.